JNJ Johnson & Johnson Common Stock
Tentang Johnson & Johnson Common Stock Tinjauan perusahaan dari Wikipedia
Johnson & Johnson adalah produsen obat-obatan, peralatan medis, dan barang konsumsi multinasional yang berkantor pusat di New Brunswick, New Jersey, Amerika Serikat yang didirikan pada tahun 1886.
Baca selengkapnya
Johnson & Johnson (NYSE: JNJ) adalah produsen obat-obatan, peralatan medis, dan barang konsumsi multinasional yang berkantor pusat di New Brunswick, New Jersey, Amerika Serikat yang didirikan pada tahun 1886.
Johnson & Johnson mendapat peringkat teratas dalam National Corporate Reputation Survey selama tujuh tahun berturut-turut hingga tahun 2005, dan termasuk salah satu perusahaan paling dihormati di dunia, menurut Majalah Barron pada tahun 2008.
Johnson & Johnson memiliki sekitar 250 anak usaha yang beroperasi di lebih dari 57 negara, dan menjual produknya ke lebih dari 175 negara. Johnson & Johnson memiliki total penjualan di seluruh dunia sebesar $65 miliar pada tahun 2011.
Johnson & Johnson termasuk merek yang menyediakan banyak obat dan pertolongan pertama, antara lain perban Band-Aid, obat Tylenol, produk bayi Johnson's baby, produk kulit dan kecantikan Neutrogena, pembersih wajah Clean & Clear dan lensa kontak Acuvue.
Pada tanggal 31 Desember 2012, Food and Drug Administration menyetujui Sirturo, obat TBC dari Johnson & Johnson, yang merupakan obat pertama untuk memerangi infeksi dalam empat puluh tahun terakhir.
Sejarah
Pendirian & Sejarah Awal
Terinspirasi dari pidato penasehat antiseptik, Joseph Lister, Robert Wood Johnson pun mengajak saudaranya, James Wood Johnson dan Edward Mead Johnson untuk memproduksi baju operasi siap pakai, pada tahun 1885. Perusahaan ini pun berproduksi pertama kali pada tahun 1886 dan resmi berdiri pada tahun 1887.
Robert Wood Johnson pun menjadi presiden pertama perusahaan ini. Ia terus berusaha meningkatkan sanitasi pada abad ke-19, dan bahkan meminjamkan namanya untuk sebuah rumah sakit di New Brunswick, New Jersey. Setelah kematiannya pada tahun 1910, ia pun digantikan oleh saudaranya, James Wood Johnson hingga 1932, dan lalu oleh anaknya, Robert Wood Johnson II.
Cucu Robert Wood Johnson, Mary Lea Johnson Richards, pun pernah muncul di label bedak bayi Johnson & Johnson. Cicitnya, Jamie Johnson, juga pernah membuat dokumenter berjudul Born Rich, yang menceritakan tentang pengalamannya tumbuh sebagai keturunan dari salah satu keluarga terkaya di dunia.
1959: McNeil Consumer Healthcare
McNeil Consumer Healthcare didirikan pada tanggal 16 Maret 1879 oleh Robert McNeil. Pada tahun 1904, salah satu anak McNeil, Robert Lincoln McNeil, bergabung dengan perusahaan ini dan bersama-sama mereka mendirikan McNeil Laboratories pada tahun 1933. Perusahaan ini berfokus pada pemasaran obat langsung ke rumah sakit, apoteker, dan dokter. Pengembangan parasetamol pun dimulai dibawah kepemimpinan Robert L. McNeil, Jr., yang nantinya menjadi direktur perusahaan ini. Pada tahun 1959, Johnson & Johnson mengakuisisi McNeil Laboratories dan setahun kemudian, perusahaan ini mampu menjual Tylenol tanpa harus didahului oleh resep untuk pertama kalinya. Pada tahun 1977, dua anak usaha pun dibentuk, yakni McNeil medicals products dan McNeil Consumer Products Company (yang lebih dikenal sebagai McNeil Consumer Healthcare). Fokus dari McNeil medicals products adalah memasarkan obat yang didahului dengan resep. Pada tahun 1993, McNeil medicals products digabungkan dengan Ortho Pharmaceutical untuk membentuk Ortho-McNeil Pharmaceutical. Pada tahun 2001, McNeil Consumer Healthcare mengganti namanya menjadi McNeil Consumer & Specialty medicals products. Namun, nama tersebut kembali diganti menjadi McNeil Consumer Healthcare. Perusahaan ini memasarkan obat yang didahului dengan resep, seperti Tylenol dan Motrin IB (ibuprofen).
1959: Cilag
Pada tahun 1933, ahli kimia asal Swiss, Bernhard Joos mendirikan sebuah laboratorium riset kecil di Schaffhausen, Swiss. Inipun menjadi dasar dari pendirian Chemische Industrie-Labor AG atau disingkat sebagai Cilag pada tanggal 12 Mei 1936. Pada tahun 1959, Cilag bergabung ke Johnson & Johnson. Pada awal abad ke-19, divisi pemasaran Cilag dan Janssen Pharmaceutica digabung untuk membentuk Janssen-Cilag. Sedangkan Cilag dan Janssen tetap beroperasi dengan namanya masing-masing. Pada bulan Agustus 2014, Cilag mengakuisisi Covagen, sebuah perusahaan biofarmasi yang berspesialisasi di pengembangan terapi berbasis protein multispesifik.
1961: Janssen Pharmaceuticals
Sejarah Janssen Pharmaceuticals dapat dilacak hingga tahun 1933. Pada tahun 1933, Constant Janssen, ayah dari Paul Janssen, mengakuisisi hak distribusi produk Richter, sebuah perusahaan farmasi asal Hungaria, untuk wilayah Belgia, Belanda, dan Kongo. Pada tanggal 23 Oktober 1934, ia pun mendirikan N.V. Produkten Richter di Turnhout. Setelah Perang Dunia II, nama produknya diganti menjadi Eupharma, walaupun nama perusahaannya tetap Richter hingga tahun 1956.
Pada tahun 1953, anaknya, Paul Janssen pun mendirikan laboratorium miliknya sendiri di lantai tiga kantor ayahnya. Pada tanggal 5 April 1956, nama perusahaan ini diganti menjadi NV Laboratoria Pharmaceutica C. Janssen. Pada tanggal 2 Mei 1958, departemen risetnya di Beerse, menjadi perusahaan yang berdiri sendiri dengan nama N.V. Research Laboratorium C. Janssen. Pada tanggal 24 Oktober 1961, perusahaan ini diakuisisi oleh Johnson & Johnson. Pada tanggal 10 Februari 1964, namanya pun diganti menjadi Janssen Pharmaceutica N.V. Antara tahun 1990 hingga 2004, Janssen Pharmaceuticals pun berekspansi ke seluruh dunia, dengan mempekerjakan hampir 28.000 di seluruh dunia. Pada tahun 2001, seluruh aktivitas riset Janssen dipindahkan ke Amerika Serikat dan dipusatkan di Johnson & Johnson Pharmaceutical Research and Development. Pada tanggal 27 Oktober 2004, Paul Janssen Research Center diperkenalkan
Pada bulan Agustus 2013, Janssen mengakuisisi Aragon Pharmaceuticals, Inc. Pada bulan November 2014, Janssen juga mengakuisisi Alios BioPharma, Inc. dengan harga $1.75 milliar. Sebagai hasilnya, Alios pun digabungkan ke divisi penyakit menular dan terapi di Janssen. Pada bulan November 2015, Janssen mengakuisisi Novira Therapeutics, Inc.
1998:DePuy
DePuy diakuisisi oleh J&J pada tahun 1998, dan lalu digabung ke Johnson & Johnson Medical Devices. Pada tanggal 14 Juni 2012, Johnson & Johnson juga menyelesaikan proses akuisisi terhadap Synthes seharga $19.7 milliar, yang lalu digabung dengan DePuy untuk membentuk DePuy Synthes Companies, yang memiliki beberapa anak usaha, yakni : Codman & Shurteff, Inc., DePuy Mitek, Inc., DePuy Orthopaedics, Inc. dan DePuy Spine, Inc.
1999: Janssen Biotech, Inc.
Janssen Biotech, Inc., sebelumnya dikenal sebagai Centocor Biotech, Inc., adalah perusahaan bioteknologi yang didirikan di Philadelphia pada tahun 1979. Pada tahun 1982, Centocor melepas sahamnya ke publik. Pada tahun 1999, Centocor resmi menjadi anak usaha Johnson & Johnson. Sejak diakuisisi, Centocor berhasil meningkatkan penjualannya dari $500 juta setahun ke lebih dari $2 milliar. Pada periode yang sama, investasi riset dan pengembangan juga ditingkatkan dari $75 juta ke lebih dari $300 juta. Pada tahun 2008, Centocor, Inc. dan Ortho Biotech Inc. digabung untuk membentuk Centocor Ortho Biotech Inc. Pada bulan Juni 2010, Centocor Ortho Biotech mengakuisisi RespiVert, sebuah perusahaan yang berfokus pada pengembangan terapi hirup untuk penyakit paru-paru. Pada bulan Juni 2011, Centocor Ortho Biotech mengganti namanya menjadi Janssen Biotech, Inc.
Ethicon, Inc
Pada tahun 1915, George F. Merson mendirikan sebuah pabrik pemroduksi benang jahit nilon dan sutra di Edinburgh. Johnson & Johnson mengakuisisi perusahaan ini pada tahun 1947, dan namanya pun diubah menjadi Ethicon Suture Laboratories. Pada tahun 1953, Ethicon berganti nama menjadi Ethicon Inc. Pada tahun 1992, Ethicon direstrukturisasi, dan Ethicon Endo-Surgery, Inc. pun dipisahkan. Selama dekade 1990an, Ethicon berdiversifikasi ke berbagai bidang baru dengan membentuk empat anak usaha yang bergerak di bidang yang berbeda. Pada tahun 2008, J&J mengumumkan rencananya untuk mengakuisisi Mentor Corporation dengan harga $1 milliar dan menggabungkannya dengan Ethicon.
Ethicon Endo-Surgery, Inc.
Ethicon Endo-Surgery adalah bagian dari Ethicon Inc. hingga tahun 1992, saat perusahaan ini dipisahkan menjadi perusahaan yang berdiri sendiri dibawah payung J&J.
2010: Crucell
Pada bulan Oktober 2010, J&J mengakuisisi Crucell dengan harga $2.4 milliar.
Ketua
Robert Wood Johnson I 1887–1910
James Wood Johnson 1910–1932
Robert Wood Johnson II 1932–1963
Philip B. Hofmann 1963–1973
Richard B. Sellars 1973–1976
James E. Burke 1976–1989
Ralph S. Larsen 1989–2002
William C. Weldon 2002–2012
Alex Gorsky 2012–sekarang
Difersifikasi
Struktur perusahaan Johnson & Johnson didasarkan pada filosofi manajemen desentralisasi. Perusahaan beroperasi di tiga segmen: Produk Konsumen, Farmasi, dan Alat Kesehatan dan Diagnostik. Komite Eksekutif pusat perusahaan mengalokasikan sumber daya dan menetapkan prioritas strategis untuk divisi tersebut. Anak perusahaan utama meliputi Ethicon (Alat Kesehatan); McNeil Laboratories, Inc, Cilag, dan Janssen Pharmaceutica (Farmasi). Pada tahun 2012, Produk Konsumen, Farmasi, dan Alat Kesehatan dan divisi Diagnostik menyumbang 22%, 37%, dan 41% dari pendapatan perusahaan, masing-masing.
Kantor pusat
Perusahaan secara historis terletak di Delaware dan Raritan Canal di New Brunswick. Perusahaan menganggap memindahkan markasnya dari New Brunswick pada tahun 1960 , tetapi memutuskan untuk tinggal di kota setelah para pejabat kota berjanji untuk gentrify pusat kota New Brunswick dengan menghancurkan bangunan tua dan membangun yang baru . Sementara New Brunswick kehilangan setidaknya satu bangunan bersejarah - penginapan mana Rutgers University mulai untuk pembangunan kembali , gentrifikasi melakukan menarik orang kembali ke New Brunswick. Johnson & Johnson disewa Henry N. Cobb dari Pei Cobb Freed & Partners untuk merancang samping kantor pusatnya , yang mengambil bentuk sebuah menara putih di sebuah taman di seberang rel kereta api dari bagian yang lebih tua dari kantor pusat . Bentangan Delaware dan Raritan kanal oleh kantor pusat perusahaan digantikan oleh hamparan Route 18 pada akhir tahun 1970, setelah perselisihan panjang. Pada tahun 2002, perusahaan ini merilis rencana mendirikan kantor pusat informasi teknologi Asia-Pasifik teknologi di New South Wales dalam lima tahun.
Kepemilikan anak perusahaan
Johnson & Johnson adalah perusahaan yang sangat terdiversifikasi dengan setidaknya 230 anak, yang mengacu pada sebagai "Johnson & Johnson Family of Companies". Beberapa anak perusahaan tersebut meliputi kepemilikan anak perusahaan sebagai berikut:
Referensi
Pranala luar
(Inggris) Situs web resmi
Sumber: Wikipedia, CC BY-SA 4.0 · Lihat di Wikipedia ↗
JNJ Cuplikan Saham Harga, kapitalisasi pasar, P/E, EPS, ROE, utang/ekuitas, kisaran 52 minggu
JNJ Grafik Harga Saham OHLCV harian dengan indikator teknis — geser, perbesar, dan sesuaikan tampilan Anda
Kinerja 10 Tahun Tren Pendapatan, laba bersih, margin, dan EPS
Valuasi Rasio P/E, P/S, P/B, EV/EBITDA — apakah sahamnya mahal atau murah?
Profitabilitas Margin kotor, operasional, dan bersih; ROE, ROA, ROIC
Kesehatan Keuangan Utang, likuiditas, solvabilitas — kekuatan neraca
Pertumbuhan Pertumbuhan Pendapatan, EPS, dan Laba Bersih: YoY, CAGR 3T, CAGR 5T
Efisiensi Modal Perputaran aset, perputaran persediaan, perputaran piutang
Dividen Yield, rasio pembayaran, riwayat dividen, CAGR 5 tahun
| Tanggal ex-dividen | Jumlah |
|---|---|
| 26 Mei 2026 | $1,3400 |
| 24 Feb. 2026 | $1,3000 |
| 25 Nov. 2025 | $1,3000 |
| 26 Agu 2025 | $1,3000 |
| 27 Mei 2025 | $1,3000 |
| 18 Feb. 2025 | $1,2400 |
| 26 Nov. 2024 | $1,2400 |
| 27 Agu 2024 | $1,2400 |
| 20 Mei 2024 | $1,2400 |
| 16 Feb. 2024 | $1,1900 |
| 20 Nov. 2023 | $1,1900 |
| 25 Agu 2023 | $1,1900 |
| 22 Mei 2023 | $1,1900 |
| 17 Feb. 2023 | $1,1300 |
| 21 Nov. 2022 | $1,1300 |
| 22 Agu 2022 | $1,1300 |
| 23 Mei 2022 | $1,1300 |
| 18 Feb. 2022 | $1,0600 |
| 22 Nov. 2021 | $1,0600 |
| 23 Agu 2021 | $1,0600 |
JNJ Konsensus Analis Opini analis bullish dan bearish, target harga 12 bulan, potensi kenaikan
- Beli Kuat 7 22,6%
- Beli 15 48,4%
- Tahan 9 29,0%
- Jual 0 0,0%
- Jual Kuat 0 0,0%
Target Harga 12 Bulan
22 analis · 2026-08-21Riwayat Pendapatan EPS aktual vs perkiraan, kejutan %, tingkat keberhasilan, tanggal pendapatan berikutnya
| Periode | EPS Aktual | EPS Estimasi | Kejutan |
|---|---|---|---|
| 30 Juni 2026 | $2.90 | $2.87 | 0.03% |
| 31 Maret 2026 | $2.70 | $2.69 | 0.01% |
| 31 Des. 2025 | $2.46 | $2.46 | -0.00% |
| 30 Sep. 2025 | $2.80 | $2.78 | 0.02% |
| 30 Juni 2025 | $2.77 | $2.71 | 0.06% |
| 31 Maret 2025 | $2.77 | $2.61 | 0.16% |
Perbandingan rekan (sub-industri GICS) Metrik utama vs rekan sektor
| Ticker | Kapitalisasi Pasar | P/E | Pendapatan YoY | Margin Bersih | ROE | Margin Kotor |
|---|---|---|---|---|---|---|
| JNJ | — | 18.8 | 6.0% | 28.5% | 35.0% | 67.9% |
| LLY | — | 46.8 | 44.7% | 31.7% | 101.2% | — |
| MRK | — | 14.5 | 1.3% | 28.1% | 36.9% | — |
| PFE | — | 18.3 | -1.7% | 12.4% | 8.9% | — |
| BMY | — | 15.6 | -0.22% | 14.6% | 40.5% | — |
| RPRX | — | 21.7 | 5.1% | 32.4% | 8.0% | — |
| ZTS | $53.46B | 20.9 | 2.3% | 28.2% | 66.0% | — |
| VTRS | — | -4.2 | -3.0% | -24.6% | -23.2% | 35.1% |
| CORT | $3.69B | 42.4 | 12.8% | 13.1% | 15.5% | — |
| ELAN | $11.25B | -48.1 | 6.2% | -4.9% | -3.5% | 55.0% |
Fundamental Lengkap Semua metrik per tahun — laporan laba rugi, neraca, arus kas
Laporan Laba Rugi 17
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $94.19B | $88.82B | $85.16B | $79.99B | $78.74B | $82.58B | $82.06B | $81.58B | $76.45B | $71.89B | $70.07B | $74.33B | |
| Cost of Revenue | $30.26B | $27.47B | $26.55B | $24.60B | $23.40B | $28.43B | $27.56B | $27.09B | $25.44B | $21.79B | $21.54B | $22.75B | |
| Gross Profit | $63.94B | $61.35B | $58.61B | $55.39B | $55.34B | $54.16B | $54.50B | $54.49B | $51.01B | $50.10B | $48.54B | $51.59B | |
| R&D Expense | $109M | $1.84B | $483M | $0 | $0 | · | · | · | · | · | · | · | |
| SG&A Expense | $23.68B | $22.87B | $21.51B | $20.25B | $20.12B | $22.08B | $22.18B | $22.54B | $21.52B | $20.07B | $21.20B | $21.95B | |
| Operating Income | · | · | · | · | · | · | · | · | · | · | · | $21.59B | |
| Interest Expense | · | · | $772M | $276M | $183M | $201M | $318M | $1.00B | $934M | $726M | $552M | $533M | |
| Interest Income | $1.06B | $1.33B | $1.26B | $490M | $53M | $111M | $357M | $611M | $385M | $368M | $128M | $67M | |
| Other Non-op | $7.21B | $-4.69B | $-6.63B | $-810M | $-526M | $-2.90B | $-2.52B | $-1.41B | $42M | $-210M | $2.06B | $70M | |
| Pretax Income | $32.58B | $16.69B | $15.06B | $19.36B | $19.18B | $16.50B | $17.33B | $18.00B | $17.67B | $19.80B | $19.20B | $20.56B | |
| Income Tax | $5.78B | $2.62B | $1.74B | $2.99B | $1.38B | $1.78B | $2.21B | $2.70B | $16.37B | $3.26B | $3.79B | $4.24B | |
| Net Income | $26.80B | $14.07B | $35.15B | $17.94B | $20.88B | $14.71B | $15.12B | $15.30B | $1.30B | $16.54B | $15.41B | $16.32B | |
| EPS (Basic) | $11.13 | $5.84 | $13.88 | $6.83 | $7.93 | $5.59 | $5.72 | $5.70 | $0.48 | $6.04 | $5.56 | $5.80 | |
| EPS (Diluted) | $11.03 | $5.79 | $13.72 | $6.73 | $7.81 | $5.51 | $5.63 | $5.61 | $0.47 | $5.93 | $5.48 | $5.70 | |
| Shares (Basic) | 2,407,400,000 | 2,407,300,000 | 2,533,500,000 | 2,625,200,000 | 2,632,100,000 | 2,632,800,000 | 2,645,100,000 | 2,681,500,000 | 2,692,000,000 | 2,737,300,000 | 2,771,800,000 | 2,815,200,000 | |
| Shares (Diluted) | 2,429,400,000 | 2,429,400,000 | 2,560,400,000 | 2,663,900,000 | 2,674,000,000 | 2,670,700,000 | 2,684,300,000 | 2,728,700,000 | 2,745,300,000 | 2,788,900,000 | 2,812,900,000 | 2,863,900,000 | |
| EBITDA | $7.50B | $7.34B | $7.49B | $6.97B | $7.39B | $7.23B | $7.01B | $6.93B | $5.64B | $3.75B | $3.75B | $25.48B |
Neraca 29
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $19.71B | $24.11B | $21.86B | $12.89B | $14.49B | $13.98B | $17.30B | $18.11B | $17.82B | $18.97B | $13.73B | $14.52B | |
| Short-term Investments | $393M | $417M | $1.07B | $9.39B | $17.12B | $11.20B | $1.98B | $1.58B | $472M | $22.93B | $24.64B | $18.57B | |
| Receivables | $17.18B | $14.84B | $14.87B | $14.04B | $15.28B | $13.58B | $14.48B | $14.10B | $13.49B | $11.70B | $10.73B | $10.98B | |
| Inventory | $14.19B | $12.44B | $11.18B | $10.27B | $10.39B | $9.34B | $9.02B | $8.60B | $8.77B | $8.14B | $8.05B | $8.18B | |
| Prepaid Expense | $4.15B | $4.08B | $4.51B | $2.88B | $3.70B | $3.13B | $2.39B | $2.70B | $2.54B | $3.28B | $3.05B | $3.49B | |
| Current Assets | $55.62B | $55.89B | $53.49B | $55.29B | $60.98B | $51.24B | $45.27B | $46.03B | $43.09B | $65.03B | $60.21B | $55.74B | |
| PP&E (Net) | $23.17B | $20.52B | $19.90B | $17.98B | $18.96B | $18.77B | $17.66B | $17.04B | $17.00B | $15.91B | $15.90B | $16.13B | |
| PP&E (Gross) | $54.36B | $48.77B | $47.78B | $43.53B | $47.68B | $46.80B | $43.33B | $41.85B | $41.47B | $37.77B | $36.65B | $36.69B | |
| Accum. Depreciation | $31.20B | $28.25B | $27.88B | $25.55B | $28.72B | $28.04B | $25.67B | $24.82B | $24.46B | $21.86B | $20.74B | $20.56B | |
| Goodwill | $48.77B | $44.20B | $36.56B | $36.05B | $25.44B | $36.39B | $33.64B | $30.45B | $31.91B | $22.80B | $21.63B | $21.83B | |
| Intangibles | $50.40B | $37.62B | $34.17B | $38.49B | $46.39B | $53.40B | $47.64B | $47.61B | $53.23B | $26.88B | $25.76B | $27.22B | |
| Other Non-current Assets | $14.37B | $11.41B | $14.15B | $9.21B | $10.22B | $6.56B | $5.70B | $4.18B | $4.97B | $4.43B | $4.41B | $3.23B | |
| Total Assets | $199.21B | $180.10B | $167.56B | $187.38B | $182.02B | $174.89B | $157.73B | $152.95B | $157.30B | $141.21B | $133.41B | $130.36B | |
| Accounts Payable | $11.99B | $10.31B | $9.63B | $9.89B | $11.05B | $9.51B | $8.54B | $7.54B | $7.31B | $6.92B | $6.67B | $7.63B | |
| Accrued Liabilities | $8.59B | $8.55B | $10.21B | $10.72B | $13.61B | $13.97B | $9.71B | $7.60B | $7.30B | $5.63B | $5.41B | $6.55B | |
| Short-term Debt | $8.49B | $5.98B | $3.45B | $12.76B | $3.77B | $2.63B | $1.20B | $2.80B | $3.91B | $4.68B | $7.00B | $3.64B | |
| Current Liabilities | $54.13B | $50.32B | $46.28B | $55.80B | $45.23B | $42.49B | $35.96B | $31.23B | $30.54B | $26.29B | $27.75B | $25.03B | |
| Capital Leases | · | · | · | · | · | · | $716M | · | · | · | · | · | |
| Deferred Tax | $6.79B | $2.45B | $3.19B | $3.99B | $7.49B | $7.21B | $5.96B | $7.51B | $8.37B | $2.91B | $2.56B | $2.45B | |
| Other Non-current Liabilities | $9.87B | $17.55B | $13.40B | $10.15B | $10.69B | $11.94B | $11.73B | $8.59B | $9.02B | $9.54B | $10.24B | $8.03B | |
| Total Liabilities | $117.67B | $108.61B | $98.78B | $110.57B | $108.00B | $111.62B | $98.26B | $93.20B | $97.14B | $70.79B | $62.26B | $60.61B | |
| Long-term Debt | $41.44B | $32.40B | $27.35B | $28.44B | $32.12B | $34.43B | · | $30.28B | $32.17B | $24.14B | · | · | |
| Total Debt | $49.93B | $38.38B | $30.80B | $41.21B | $35.88B | $35.27B | $27.70B | $33.08B | $36.08B | $27.13B | $19.86B | $18.76B | |
| Common Stock | $3.12B | $3.12B | $3.12B | $3.12B | $3.12B | $3.12B | $3.12B | $3.12B | $3.12B | $3.12B | $3.12B | $3.12B | |
| Retained Earnings | $168.98B | $155.79B | $153.84B | $128.34B | $123.06B | $113.89B | $110.66B | $106.22B | $101.79B | $110.55B | $103.88B | $97.25B | |
| Treasury Stock | $75.62B | $75.68B | $75.66B | $41.69B | $39.10B | $38.49B | $38.42B | $34.36B | $31.55B | $28.35B | $22.68B | $19.89B | |
| AOCI | $-14.93B | $-11.74B | $-12.53B | $-12.97B | $-13.06B | $-15.24B | $-15.89B | $-15.22B | $-13.20B | $-14.90B | $-13.16B | $-10.72B | |
| Stockholders' Equity | $81.54B | $71.49B | $68.77B | $76.80B | $74.02B | $63.28B | $59.47B | $59.75B | $60.16B | $70.42B | $71.15B | $69.75B | |
| Liabilities + Equity | $199.21B | $180.10B | $167.56B | $187.38B | $182.02B | $174.89B | $157.73B | $152.95B | $157.30B | $141.21B | $133.41B | $130.36B |
Arus Kas 18
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $7.50B | $7.34B | $7.49B | $6.97B | $7.39B | $7.23B | $7.01B | $6.93B | $5.64B | $3.75B | $3.75B | $3.90B | |
| Stock-based Comp | $1.35B | $1.18B | $1.16B | $1.14B | $1.14B | $1.00B | $977M | $978M | $962M | $878M | $874M | $792M | |
| Deferred Tax | $1.54B | $-2.18B | $-4.19B | $-1.66B | $-2.08B | $-1.14B | $-2.48B | $-1.02B | $2.41B | $-341M | $-270M | $441M | |
| Amort. of Intangibles | $4.60B | $4.50B | $4.50B | $3.90B | $4.20B | $4.70B | $4.50B | $4.40B | $3.00B | $1.20B | $1.20B | $1.40B | |
| Restructuring | $228M | $234M | $489M | $275M | $209M | $247M | $266M | $251M | $309M | $491M | $509M | $0 | |
| Other Non-cash | $-12.67B | $3.87B | $-16.82B | $-3.19B | $-3.91B | $1.73B | $2.79B | $13M | $10.75B | $-2.06B | $-480M | $-2.98B | |
| Operating Cash Flow | $24.53B | $24.27B | $22.79B | $21.19B | $23.41B | $23.54B | $23.42B | $22.20B | $21.06B | $18.77B | $19.57B | $18.71B | |
| CapEx | $4.83B | $4.42B | $4.54B | $4.01B | $3.65B | $3.35B | $3.50B | $3.67B | $3.28B | $3.23B | $3.46B | $3.71B | |
| Investing Cash Flow | $-23.59B | $-18.60B | $878M | $-12.37B | $-8.68B | $-20.82B | $-6.19B | $-3.17B | $-14.87B | $-4.76B | $-7.74B | $-12.30B | |
| Debt Issued | $9.14B | $6.66B | $0 | $2M | $5M | $7.43B | $3M | $5M | $8.99B | $12.00B | $75M | $2.10B | |
| Net Debt Issued | $7.38B | $5.21B | $-1.55B | $-2.13B | $-1.80B | $6.37B | $-2.82B | $-1.55B | $7.21B | $9.78B | $7M | $254M | |
| Stock Repurchased | $5.95B | $2.43B | $5.05B | $6.04B | $3.46B | $3.22B | $6.75B | $5.87B | $6.36B | $8.98B | $5.29B | $7.12B | |
| Net Stock Activity | $-5.95B | $-2.43B | $-5.05B | $-6.04B | $-3.46B | $-3.22B | $-6.75B | $-5.87B | $-6.36B | $-8.98B | $-5.29B | $-7.12B | |
| Financing Cash Flow | $-5.54B | $-3.13B | $-15.82B | $-8.87B | $-14.05B | $-6.12B | $-18.02B | $-18.51B | $-7.67B | $-8.55B | $-11.14B | $-12.50B | |
| Net Change in Cash | $-4.40B | $2.25B | $7.73B | $-360M | $502M | $-3.32B | $-802M | $283M | $-1.15B | $5.24B | $-791M | $-6.40B | |
| Taxes Paid | $6.54B | $6.71B | $8.57B | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $19.70B | $19.84B | $18.25B | $17.18B | $19.76B | $20.19B | $19.92B | $18.53B | $17.78B | $15.54B | $15.82B | $14.76B | |
| Levered FCF | · | · | $17.56B | $16.96B | $19.59B | $20.01B | $19.64B | $17.68B | $17.71B | $14.93B | $15.37B | $14.33B |
Profitabilitas 8
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 67.9% | 69.1% | 68.8% | 67.3% | 68.2% | 65.6% | 66.4% | 66.8% | 66.8% | 69.8% | 69.3% | 69.4% | |
| Operating Margin | · | · | · | · | · | · | · | · | · | · | · | 29.0% | |
| Net Margin | 28.5% | 15.8% | 41.3% | 18.9% | 22.3% | 17.8% | 18.4% | 18.8% | 1.7% | 23.0% | 22.0% | 22.0% | |
| Pretax Margin | 34.6% | 18.8% | 17.7% | 22.9% | 24.3% | 20.0% | 21.1% | 22.1% | 23.1% | 27.6% | 27.4% | 27.7% | |
| EBITDA Margin | 8.0% | 8.3% | 8.8% | 7.3% | 7.9% | 8.8% | 8.5% | 8.5% | 7.4% | 5.2% | 5.3% | 34.3% | |
| ROA | 14.1% | 8.1% | 19.8% | 9.7% | 11.7% | 8.8% | 9.7% | 9.9% | 0.87% | 12.0% | 11.7% | 12.4% | |
| ROE | 35.0% | 20.1% | 48.3% | 23.4% | 28.9% | 23.0% | 25.7% | 24.6% | 2.0% | 23.4% | 21.9% | 22.7% | |
| ROIC | · | · | · | · | · | · | · | · | · | · | · | 19.4% |
Likuiditas & Solvabilitas 5
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.0 | 1.1 | 1.2 | 1.0 | 1.3 | 1.2 | 1.3 | 1.5 | 1.4 | 2.5 | 2.2 | 2.4 | |
| Quick Ratio | 0.7 | 0.8 | 0.8 | 0.7 | 1.0 | 0.9 | 0.9 | 1.1 | 1.0 | 2.0 | 1.8 | 1.8 | |
| Debt / Equity | 0.6 | 0.5 | 0.4 | 0.5 | 0.5 | 0.6 | 0.5 | 0.6 | 0.6 | 0.4 | 0.3 | 0.3 | |
| LT Debt / Equity | 0.5 | 0.4 | 0.4 | 0.4 | 0.4 | 0.5 | 0.4 | 0.5 | 0.5 | 0.3 | 0.2 | 0.2 | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | · | · | 40.5 |
Efisiensi 3
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.6 | |
| Inventory Turnover | 2.3 | 2.3 | 2.5 | 2.7 | 3.0 | 3.1 | 3.1 | 3.1 | 3.0 | 2.7 | 2.7 | 2.8 | |
| Receivables Turnover | 5.9 | 6.0 | 5.9 | 6.0 | 6.5 | 5.9 | 5.7 | 5.9 | 6.1 | 6.4 | 6.5 | 6.5 |
Tingkat Pertumbuhan 9
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 6.0% | 4.3% | 6.5% | 1.6% | -4.7% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 5.6% | 4.1% | 1.0% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 2.7% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | 90.5% | -57.8% | 103.9% | -13.8% | 41.7% | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | 17.9% | -9.5% | 35.5% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | 14.9% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | 90.6% | -60.0% | 95.9% | -14.1% | 41.9% | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | 14.3% | -12.3% | 33.7% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | 12.7% | · | · | · | · | · | · | · | · | · | · | · |
Valuasi (TTM) 4
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $94.19B | $88.82B | $85.16B | $79.99B | $78.74B | $82.58B | $82.06B | $81.58B | $76.45B | $71.89B | $70.07B | $74.33B | |
| Net Income TTM | $26.80B | $14.07B | $35.15B | $17.94B | $20.88B | $14.71B | $15.12B | $15.30B | $1.30B | $16.54B | $15.41B | $16.32B | |
| P/E | 18.8 | 25.1 | 11.4 | 26.2 | 21.9 | 28.6 | 25.9 | 22.7 | 297.3 | 19.4 | 18.7 | 18.4 | |
| Earnings Yield | 5.3% | 4.0% | 8.8% | 3.8% | 4.6% | 3.5% | 3.9% | 4.4% | 0.34% | 5.1% | 5.3% | 5.4% |
Laporan Laba Rugi 15
| Metrik | Tren | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $25.31B | $24.06B | $24.56B | $23.99B | $23.74B | $21.89B | $22.52B | $22.47B | $22.45B | $21.38B | $19.32B | $21.52B | $20.89B | $10.22B | |
| Cost of Revenue | $8.05B | $8.11B | $7.97B | $7.30B | $7.63B | $7.36B | $7.13B | $6.96B | $6.87B | $6.51B | $5.81B | $6.46B | $6.69B | $2.02B | |
| Gross Profit | $17.26B | $15.96B | $16.60B | $16.69B | $16.11B | $14.54B | $15.39B | $15.51B | $15.58B | $14.87B | $13.51B | $15.06B | $14.21B | $8.21B | |
| SG&A Expense | $6.43B | $6.03B | $6.75B | $5.92B | $5.89B | $5.11B | $6.45B | $5.48B | $5.68B | $5.26B | $5.27B | $5.40B | $4.91B | $2.65B | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $155M | · | $346M | $212M | · | |
| Interest Income | $219M | $229M | $237M | $227M | $260M | $332M | $281M | $292M | $395M | $364M | $715M | $326M | $198M | $389M | |
| Other Non-op | $-331M | $-294M | $-483M | $478M | $-107M | $7.32B | $161M | $-1.80B | $-653M | $-2.40B | $-180M | $384M | $-6.94B | $-1.52B | |
| Pretax Income | $6.75B | $5.99B | $4.97B | $7.49B | $6.49B | $13.63B | $3.89B | $3.34B | $5.75B | $3.71B | $4.18B | $6.31B | $-1.29B | $228M | |
| Income Tax | $1.21B | $755M | $-150M | $2.34B | $954M | $2.63B | $456M | $644M | $1.06B | $459M | $889M | $930M | $-796M | $18M | |
| Net Income | $5.53B | $5.24B | $5.12B | $5.15B | $5.54B | $11.00B | $3.43B | $2.69B | $4.69B | $3.25B | $24.93B | $5.14B | $-68M | $1.78B | |
| EPS (Basic) | $2.30 | $2.17 | $2.12 | $2.14 | $2.30 | $4.57 | $1.42 | $1.12 | $1.95 | $1.35 | $9.97 | $1.98 | $-0.03 | $0.69 | |
| EPS (Diluted) | $2.27 | $2.14 | $2.08 | $2.12 | $2.29 | $4.54 | $1.41 | $1.11 | $1.93 | $1.34 | $9.86 | $1.96 | $-0.03 | $0.68 | |
| Shares (Basic) | 2,407,400,000 | 2,408,700,000 | -4,814,400,000 | 2,408,300,000 | 2,406,300,000 | 2,407,200,000 | -4,814,900,000 | 2,407,200,000 | 2,406,800,000 | 2,408,200,000 | -5,299,600,000 | 2,598,400,000 | 2,605,500,000 | -5,265,200,000 | |
| Shares (Diluted) | 2,440,100,000 | 2,445,200,000 | -4,842,100,000 | 2,428,600,000 | 2,419,100,000 | 2,423,800,000 | -4,850,600,000 | 2,427,900,000 | 2,422,000,000 | 2,430,100,000 | -5,337,300,000 | 2,625,700,000 | 2,605,500,000 | -5,343,200,000 | |
| EBITDA | · | $2.00B | · | · | · | $1.77B | · | · | · | $1.81B | · | · | $1.88B | · |
Neraca 28
| Metrik | Tren | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $20.42B | $21.69B | $19.71B | $18.23B | $18.58B | $38.47B | $24.11B | $19.98B | $24.88B | $25.47B | · | $21.18B | $19.17B | · | |
| Short-term Investments | $336M | $363M | $393M | $331M | $303M | $307M | $417M | $317M | $597M | $745M | · | $7.32B | $5.44B | · | |
| Receivables | $19.05B | $17.72B | $17.18B | $17.61B | $17.85B | $16.02B | $14.84B | $16.17B | $15.79B | $14.95B | · | $16.78B | $16.35B | · | |
| Inventory | $15.14B | $14.58B | $14.19B | $14.15B | $13.41B | $12.66B | $12.44B | $12.60B | $12.17B | $11.38B | · | $12.89B | $12.81B | · | |
| Prepaid Expense | $4.83B | $4.82B | $4.15B | $4.29B | $4.36B | $4.09B | $4.08B | $4.17B | $4.38B | $4.46B | · | $2.40B | $2.92B | · | |
| Current Assets | $59.77B | $59.17B | $55.62B | $54.61B | $54.50B | $71.55B | $55.89B | $53.25B | $57.82B | $57.00B | · | $60.57B | $64.39B | · | |
| PP&E (Net) | $23.58B | $23.27B | $23.17B | $22.34B | $21.95B | $20.87B | $20.52B | $20.48B | $19.75B | $19.63B | · | $20.58B | $20.17B | · | |
| PP&E (Gross) | $55.52B | $54.70B | $54.36B | $53.38B | $52.47B | $49.88B | $48.77B | $49.27B | $48.03B | $47.59B | · | $51.22B | $50.37B | · | |
| Accum. Depreciation | $31.94B | $31.43B | $31.20B | $31.04B | $30.52B | $29.01B | $28.25B | $28.80B | $28.29B | $27.95B | · | $30.64B | $30.19B | · | |
| Goodwill | $48.48B | $48.56B | $48.77B | $48.05B | $48.12B | $44.47B | $44.20B | $44.80B | $44.25B | $36.62B | $36.56B | $45.44B | $45.58B | $36.05B | |
| Intangibles | $48.23B | $49.06B | $50.40B | $48.74B | $49.84B | $36.76B | $37.62B | $39.49B | $39.73B | $34.29B | · | $46.25B | $47.45B | · | |
| Other Non-current Assets | $14.27B | $14.11B | $14.37B | $12.42B | $12.19B | $11.53B | $11.41B | $10.92B | $10.54B | $14.12B | · | $10.08B | $9.57B | · | |
| Total Assets | $201.06B | $200.89B | $199.21B | $192.82B | $193.39B | $193.67B | $180.10B | $178.29B | $181.09B | $171.97B | · | $191.69B | $195.97B | · | |
| Accounts Payable | $9.22B | $10.46B | $11.99B | $9.62B | $9.46B | $9.54B | $10.31B | $8.95B | $8.85B | $8.17B | · | $10.44B | $9.91B | · | |
| Accrued Liabilities | $9.46B | $7.40B | $8.59B | $7.60B | $7.40B | $7.91B | $8.55B | $11.45B | $10.54B | $10.32B | · | $10.61B | $11.20B | · | |
| Short-term Debt | $11.69B | $17.46B | $8.49B | $6.39B | $11.53B | $13.90B | $5.98B | $4.46B | $9.86B | $8.55B | · | $11.70B | $17.98B | · | |
| Current Liabilities | $54.90B | $57.72B | $54.13B | $50.87B | $54.18B | $56.90B | $50.32B | $51.76B | $53.93B | $48.73B | · | $54.17B | $60.37B | · | |
| Deferred Tax | $6.61B | $7.01B | $6.79B | $5.99B | $3.80B | $2.43B | $2.45B | $2.95B | $2.63B | $3.17B | · | $3.63B | $4.42B | · | |
| Other Non-current Liabilities | $10.10B | $10.21B | $9.87B | $9.93B | $10.26B | $10.44B | $17.55B | $14.92B | $14.09B | $15.07B | · | $14.58B | $14.42B | · | |
| Total Liabilities | $116.09B | $119.71B | $117.67B | $113.54B | $114.92B | $115.56B | $108.61B | $108.13B | $109.55B | $101.95B | · | $115.28B | $125.10B | · | |
| Long-term Debt | · | · | $41.44B | · | · | · | $32.40B | · | · | · | · | · | · | · | |
| Total Debt | $49.04B | $54.99B | · | $45.80B | $50.76B | $52.25B | · | $35.75B | $41.49B | $33.63B | · | · | · | · | |
| Common Stock | $3.12B | $3.12B | $3.12B | $3.12B | $3.12B | $3.12B | $3.12B | $3.12B | $3.12B | $3.12B | · | $3.12B | $3.12B | · | |
| Retained Earnings | $171.66B | $169.16B | $168.98B | $167.28B | $165.37B | $162.63B | $155.79B | $155.18B | $155.36B | $153.38B | · | $129.38B | $124.56B | · | |
| Treasury Stock | $75.86B | $76.26B | $75.62B | $75.89B | $75.71B | $75.91B | $75.68B | $75.62B | $75.69B | $75.71B | $75.66B | $44.22B | $44.18B | $41.69B | |
| AOCI | $-13.95B | $-14.83B | $-14.93B | $-15.24B | $-14.30B | $-11.74B | $-11.74B | $-12.52B | $-11.25B | $-10.77B | · | $-13.13B | $-12.63B | · | |
| Stockholders' Equity | $84.97B | $81.19B | $81.54B | $79.28B | $78.47B | $78.11B | $71.49B | $70.16B | $71.54B | $70.02B | $68.77B | $75.15B | $70.87B | $76.80B | |
| Liabilities + Equity | $201.06B | $200.89B | $199.21B | $192.82B | $193.39B | $193.67B | $180.10B | $178.29B | $181.09B | $171.97B | · | $191.69B | $195.97B | · |
Arus Kas 17
| Metrik | Tren | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $1.96B | $2.00B | $2.01B | $1.78B | $1.94B | $1.77B | $1.90B | $1.85B | $1.78B | $1.81B | $1.84B | · | $1.88B | $1.77B | |
| Stock-based Comp | $458M | $300M | $309M | $347M | $410M | $288M | $238M | $295M | $341M | $302M | $178M | · | $306M | $213M | |
| Deferred Tax | $-479M | $159M | $-3.68B | $2.22B | $825M | $2.17B | $-16M | $90M | $-695M | $-1.56B | $-2.41B | · | $-1.54B | $825M | |
| Amort. of Intangibles | $1.20B | $1.20B | $1.20B | $1.00B | $1.30B | $1.10B | $1.10B | $1.20B | $1.10B | $1.10B | $1.20B | $1.10B | $1.10B | $500M | |
| Restructuring | $34M | $32M | $84M | $63M | $64M | $17M | $42M | $41M | $-13M | $164M | $144M | $145M | $130M | $67M | |
| Other Non-cash | · | $-5.18B | · | · | · | $-11.06B | · | · | · | $-153M | · | · | $2.68B | · | |
| Operating Cash Flow | $8.62B | $2.51B | $7.31B | $9.17B | $3.88B | $4.17B | $6.98B | $7.99B | $5.63B | $3.66B | $7.86B | · | $3.26B | $5.35B | |
| CapEx | $1.32B | $1.05B | $1.84B | $1.16B | $1.04B | $795M | $1.61B | $1.03B | $976M | $807M | $1.59B | · | $863M | $1.59B | |
| Investing Cash Flow | $-1.11B | $-1.04B | $-4.49B | $-542M | $-18.26B | $-297M | $-1.32B | $-3.13B | $-13.69B | $-464M | $-1.20B | · | $3.31B | $-4.40B | |
| Debt Issued | $0 | $0 | $0 | $0 | $0 | $9.14B | $0 | $1M | $6.66B | $2M | $0 | · | $7.67B | $1M | |
| Net Debt Issued | · | $0 | · | · | · | $9.14B | · | · | · | $1M | · | · | $7.17B | · | |
| Stock Repurchased | $221M | $4.03B | $1.92B | $1.90B | $0 | $2.13B | $282M | $539M | $136M | $1.48B | $216M | · | $3.54B | $1.32B | |
| Net Stock Activity | · | $-4.03B | · | · | · | $-2.13B | · | · | · | $-1.48B | · | · | $-3.54B | · | |
| Financing Cash Flow | $-8.78B | $530M | $-1.37B | $-8.93B | $-5.67B | $10.42B | $-1.34B | $-9.88B | $7.54B | $546M | $-4.66B | · | $6.14B | $1.70B | |
| Net Change in Cash | $-1.27B | $1.98B | $1.48B | $-346M | $-19.90B | $14.37B | $4.12B | $-4.90B | $-595M | $3.61B | $2.13B | · | $12.74B | $2.77B | |
| Free Cash Flow | · | $1.47B | · | · | · | $3.38B | · | · | · | $2.85B | · | · | $2.39B | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $2.71B | · | · | $2.37B | · |
Profitabilitas 6
| Metrik | Tren | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 68.2% | 66.3% | · | 69.6% | 67.9% | 66.4% | · | 69.0% | 69.4% | 69.5% | · | 67.8% | 66.1% | · | |
| Net Margin | 21.9% | 21.8% | · | 21.5% | 23.3% | 50.2% | · | 12.0% | 20.9% | 15.2% | · | 20.2% | -0.27% | · | |
| Pretax Margin | 26.7% | 24.9% | · | 31.2% | 27.3% | 62.3% | · | 14.8% | 25.6% | 17.4% | · | 26.5% | -3.0% | · | |
| EBITDA Margin | · | 8.3% | · | · | · | 8.1% | · | · | · | 8.5% | · | · | 7.6% | · | |
| ROA | 2.8% | 2.6% | · | 2.8% | 3.0% | 6.0% | · | 1.6% | 2.5% | 1.8% | · | · | · | · | |
| ROE | 6.8% | 6.6% | · | 6.9% | 7.4% | 14.8% | · | 3.8% | 6.4% | 4.6% | · | · | · | · |
Likuiditas & Solvabilitas 4
| Metrik | Tren | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.1 | 1.0 | · | 1.1 | 1.0 | 1.3 | · | 1.0 | 1.1 | 1.2 | · | · | · | · | |
| Quick Ratio | 0.7 | 0.7 | · | 0.7 | 0.7 | 1.0 | · | 0.7 | 0.8 | 0.8 | · | · | · | · | |
| Debt / Equity | 0.6 | 0.7 | · | 0.6 | 0.6 | 0.7 | · | 0.5 | 0.6 | 0.5 | · | · | · | · | |
| LT Debt / Equity | 0.4 | 0.5 | · | 0.5 | 0.5 | 0.5 | · | 0.4 | 0.4 | 0.4 | · | · | · | · |
Efisiensi 3
| Metrik | Tren | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | · | · | · | |
| Inventory Turnover | 0.6 | 0.6 | · | 0.5 | 0.6 | 0.6 | · | 0.6 | 0.5 | 0.5 | · | · | · | · | |
| Receivables Turnover | 1.4 | 1.4 | · | 1.4 | 1.4 | 1.4 | · | 1.5 | 1.4 | 1.4 | · | · | · | · |
Valuasi (TTM) 4
| Metrik | Tren | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $97.11B | $93.69B | · | $92.10B | $90.55B | $88.19B | · | $87.70B | $86.58B | $85.65B | · | $86.14B | · | · | |
| Net Income TTM | $21.46B | $26.92B | · | $24.38B | $23.92B | $21.63B | · | $14.68B | $38.02B | $38.48B | · | $13.05B | · | · | |
| P/E | 28.9 | 21.7 | · | 17.9 | 15.4 | 18.4 | · | 26.7 | 9.6 | 10.4 | · | 33.5 | · | · | |
| Earnings Yield | 3.5% | 4.6% | · | 5.6% | 6.5% | 5.5% | · | 3.8% | 10.4% | 9.6% | · | 3.0% | · | · |
Laporan Keuangan Laporan laba rugi, neraca, arus kas — tahunan, 5 tahun terakhir
Laporan Laba Rugi
| 2025-12-28 | 2024-12-29 | 2023-12-31 | 2023-01-01 | 2022-01-02 | |
|---|---|---|---|---|---|
| Pendapatan | $94.19B | $88.82B | $85.16B | $79.99B | $78.74B |
| Margin Kotor % | 67.9% | 69.1% | 68.8% | 67.3% | 68.2% |
| Laba Bersih | $26.80B | $14.07B | $35.15B | $17.94B | $20.88B |
| EPS Dilusian | $11.03 | $5.79 | $13.72 | $6.73 | $7.81 |
Neraca
| 2025-12-28 | 2024-12-29 | 2023-12-31 | 2023-01-01 | 2022-01-02 | |
|---|---|---|---|---|---|
| Utang / Ekuitas | 0.6 | 0.5 | 0.4 | 0.5 | 0.5 |
| Rasio Lancar | 1.0 | 1.1 | 1.2 | 1.0 | 1.3 |
| Rasio Cepat | 0.7 | 0.8 | 0.8 | 0.7 | 1.0 |
Arus Kas
| 2025-12-28 | 2024-12-29 | 2023-12-31 | 2023-01-01 | 2022-01-02 | |
|---|---|---|---|---|---|
| Arus Kas Bebas | $19.70B | $19.84B | $18.25B | $17.18B | $19.76B |
Berita Terbaru Berita utama terbaru yang menyebutkan perusahaan ini
- J&J's Proposed $5.5 Billion Talc Settlement May "Lift Remaining Overhang" On Shares, Says Guggenheim
- Jim Cramer Said To Buy Johnson & Johnson (NYSE:JNJ)’s Shares – Here’s What Happened Next
- Better Dividend King to Buy Right Now: AbbVie or Johnson & Johnson?
- J&J Finally Has a Rival to da Vinci. 1 Number in Intuitive Surgical’s Last Quarter Says It Won’t Be Enough to Move the Needle for JNJ Stock.
- This Dividend King Has Raised Its Payout for More Than 60 Straight Years. But Is the Stock Still a Buy?
- 64 With $1.1 Million in a Traditional IRA. Yield Volatility Is Back. Here’s Where I’m Allocating Capital
- Why a Dividend Portfolio That Pays Your Rent May Beat Homeownership by $500,000 Over 20 Years
- Johnson & Johnson Just Paid $1 Billion for a Technology That Could Crack One of Cancer's Most "Undruggable" Targets. Why That's Very Good News for Investors.
- AbbVie Reports Promising New Clinical Updates. Here's What It Means for the Company's Dividend.
- Why Johnson & Johnson May Be the Closest Thing Investors Can Find to a Bulletproof Dividend Stock
Metrik Saya Daftar pantauan pribadi Anda — baris yang dipilih dari Fundamental Lengkap
Pilih metrik yang penting bagi Anda — klik ➕ di sebelah baris mana pun di Fundamental Lengkap di atas.
Pilihan Anda disimpan dan mengikuti Anda di semua ticker.
Pemilik institusional (13F) 5.077 pengaju · $274.8B total · Per tanggal 30 Juni 2026
Institusi yang melaporkan kepemilikan saham ini dalam SEC Form 13F triwulanan mereka. Hanya posisi panjang; satu pengaju dapat muncul dua kali untuk leg opsi terpisah. Kaki put/call offset yang besar biasanya mencerminkan pembuatan pasar atau inventaris yang dilindungi, bukan keyakinan arah.
| Posisi baru | Posisi yang keluar | Meningkat | Menurun | Perubahan bersih saham |
|---|---|---|---|---|
| 167 (-178 vs Kuartal sebelumnya) | 107 (-8 vs Kuartal sebelumnya) | 2.028 (+340 vs Kuartal sebelumnya) | 1.873 (-286 vs Kuartal sebelumnya) | +46.7M |
Dibandingkan dengan Q1 2026. Pengajuan Formulir 13F SEC jatuh tempo dalam waktu 45 hari setelah akhir kuartal ditambah kelonggaran singkat untuk pengaju terlambat — kuartal yang masih dalam jangka waktu tersebut dilewati demi pasangan terakhir yang dilaporkan sepenuhnya.
| Institusi | Nilai | Saham | % dari 13F yang dilacak | Tipe |
|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $39.930.782.204 | 157.226.374 | 14,53% | Saham |
| STATE STREET CORP | $33.975.097.069 | 133.776.025 | 12,36% | Saham |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $16.348.256.139 | 64.370.816 | 5,95% | Saham |
| GEODE CAPITAL MANAGEMENT, LLC | $12.958.440.117 | 51.166.740 | 4,71% | Saham |
| NORGES BANK | $8.082.616.583 | 31.825.084 | 2,94% | Saham |
| WELLINGTON MANAGEMENT GROUP LLP | $5.549.231.802 | 21.849.950 | 2,02% | Saham |
| STATE FARM MUTUAL AUTOMOBILE INSURANCE CO | $5.544.876.216 | 21.832.800 | 2,02% | Saham |
| Capital World Investors | $3.864.157.554 | 15.215.015 | 1,41% | Saham |
| DIMENSIONAL FUND ADVISORS LP | $3.484.562.326 | 13.720.369 | 1,27% | Saham |
| VANGUARD FIDUCIARY TRUST CO | $3.432.930.268 | 13.517.070 | 1,25% | Saham |
| Fisher Asset Management, LLC | $3.379.593.434 | 13.307.056 | 1,23% | Saham |
| FMR LLC | $3.354.629.851 | 13.208.764 | 1,22% | Saham |
| AMERIPRISE FINANCIAL INC | $2.752.349.971 | 10.837.150 | 1,00% | Saham |
| HighTower Advisors, LLC | $2.512.466.026 | 9.892.767 | 0,91% | Saham |
| Capital Research Global Investors | $2.073.562.156 | 8.164.545 | 0,75% | Saham |
| UBS Group AG | $1.983.817.321 | 7.811.227 | 0,72% | Saham |
| Grantham, Mayo, Van Otterloo & Co. LLC | $1.805.761.048 | 7.110.133 | 0,66% | Saham |
| BANK OF AMERICA CORP /DE/ | $1.782.933.090 | 7.020.251 | 0,65% | Saham |
| BlackRock, Inc. | $1.750.119.461 | 6.891.048 | 0,64% | Saham |
| Swiss National Bank | $1.725.321.576 | 6.793.407 | 0,63% | Saham |
| Ninety One UK Ltd | $1.721.057.957 | 6.776.620 | 0,63% | Saham |
| JOURNEY STRATEGIC WEALTH LLC | $1.705.878.125 | 6.978.719 | 0,62% | Saham |
| ALLIANCEBERNSTEIN L.P. | $1.678.634.257 | 6.867.265 | 0,61% | Saham |
| RAYMOND JAMES FINANCIAL INC | $1.671.784.874 | 6.582.608 | 0,61% | Saham |
| Legal & General Group Plc | $1.647.461.740 | 6.486.836 | 0,60% | Saham |
| Mitsubishi UFJ Asset Management Co., Ltd. | $1.542.961.890 | 6.075.370 | 0,56% | Saham |
| Sumitomo Mitsui Trust Group, Inc. | $1.437.687.090 | 5.660.854 | 0,52% | Saham |
| Clearbridge Investments, LLC | $1.352.022.842 | 5.323.554 | 0,49% | Saham |
| CANADA PENSION PLAN INVESTMENT BOARD | $1.342.031.830 | 5.284.214 | 0,49% | Saham |
| Vanguard Global Advisers, LLC | $1.331.855.506 | 5.244.145 | 0,48% | Saham |
| National Pension Service | $1.327.493.063 | 5.226.968 | 0,48% | Saham |
| LPL Financial LLC | $1.283.854.730 | 5.055.143 | 0,47% | Saham |
| California Public Employees Retirement System | $1.262.226.329 | 4.969.982 | 0,46% | Saham |
| VANGUARD ASSET MANAGEMENT, Ltd | $1.259.708.724 | 4.960.069 | 0,46% | Saham |
| PeakShares LLC | $1.248.770.000 | 4.917 | 0,45% | Saham |
| ENVESTNET ASSET MANAGEMENT INC | $1.247.239.584 | 4.910.996 | 0,45% | Saham |
| TD Asset Management Inc | $1.242.199.016 | 4.891.125 | 0,45% | Saham |
| WELLS FARGO & COMPANY/MN | $1.148.432.649 | 4.521.923 | 0,42% | Saham |
| VANGUARD GROUP INC | $1.093.795.525 | 5.285.313 | 0,40% | Saham |
| GOLDMAN SACHS GROUP INC | $1.077.672.069 | 4.243.305 | 0,39% | Saham |
| MACKENZIE FINANCIAL CORP | $1.033.234.532 | 4.068.333 | 0,38% | Saham |
| NEUBERGER BERMAN GROUP LLC | $1.018.530.514 | 4.007.808 | 0,37% | Saham |
| JANE STREET GROUP, LLC | $974.914.639 | 3.838.700 | 0,35% | Opsi jual |
| RHUMBLINE ADVISERS | $960.197.598 | 3.780.752 | 0,35% | Saham |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $951.486.414 | 3.746.452 | 0,35% | Saham |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $915.044.518 | 3.743.432 | 0,33% | Saham |
| NORDEA INVESTMENT MANAGEMENT AB | $827.927.813 | 3.251.749 | 0,30% | Saham |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $781.557.545 | 3.197.339 | 0,28% | Saham |
| Independent Franchise Partners LLP | $772.877.948 | 3.043.186 | 0,28% | Saham |
| PNC Financial Services Group, Inc. | $772.728.106 | 3.042.596 | 0,28% | Saham |
| BARCLAYS PLC | $752.517.682 | 2.963.018 | 0,27% | Saham |
| AMERICAN CENTURY COMPANIES INC | $748.128.061 | 2.945.732 | 0,27% | Saham |
| MORGAN STANLEY | $729.254.283 | 2.871.419 | 0,27% | Saham |
| NEW YORK STATE COMMON RETIREMENT FUND | $722.251.569 | 2.843.846 | 0,26% | Saham |
| BNP PARIBAS FINANCIAL MARKETS | $710.953.967 | 2.799.362 | 0,26% | Saham |
| JANE STREET GROUP, LLC | $702.963.563 | 2.767.900 | 0,26% | Opsi beli |
| Bank Julius Baer & Co. Ltd, Zurich | $694.518.672 | 2.722.956 | 0,25% | Saham |
| VICTORY CAPITAL MANAGEMENT INC | $665.637.275 | 2.620.929 | 0,24% | Saham |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $651.838.132 | 2.566.595 | 0,24% | Saham |
| Caisse de depot et placement du Quebec | $573.768.008 | 2.259.196 | 0,21% | Saham |
| PRUDENTIAL FINANCIAL INC | $559.140.352 | 2.201.600 | 0,20% | Saham |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $551.532.313 | 2.206.076 | 0,20% | Saham |
| AVIVA PLC | $549.263.205 | 2.162.709 | 0,20% | Saham |
| 1832 Asset Management L.P. | $549.091.775 | 2.162.034 | 0,20% | Saham |
| Ensign Peak Advisors, Inc | $524.358.145 | 2.064.646 | 0,19% | Saham |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $519.978.432 | 2.047.401 | 0,19% | Saham |
| Capital International Investors | $518.230.847 | 2.040.519 | 0,19% | Saham |
| Bahl & Gaynor LLC | $500.543.363 | 1.970.876 | 0,18% | Saham |
| Robeco Institutional Asset Management B.V. | $499.332.703 | 1.966.109 | 0,18% | Saham |
| FIFTH THIRD BANCORP | $493.708.019 | 1.943.962 | 0,18% | Saham |
| Assenagon Asset Management S.A. | $492.540.275 | 1.939.364 | 0,18% | Saham |
| Point72 Asset Management, L.P. | $483.838.247 | 1.905.100 | 0,18% | Opsi jual |
| ACR Alpine Capital Research, LLC | $476.346.389 | 1.875.601 | 0,17% | Saham |
| Eurizon Capital SGR S.p.A. | $474.571.274 | 1.860.763 | 0,17% | Saham |
| Pictet Asset Management Holding SA | $470.681.350 | 1.853.258 | 0,17% | Saham |
| Korea Investment CORP | $469.771.865 | 1.849.714 | 0,17% | Saham |
| US BANCORP \DE\ | $457.121.111 | 1.799.902 | 0,17% | Saham |
| CITIGROUP INC | $451.787.233 | 1.778.900 | 0,16% | Opsi jual |
| Quantinno Capital Management LP | $446.029.503 | 1.756.229 | 0,16% | Saham |
| PineStone Asset Management Inc. | $440.344.361 | 1.733.844 | 0,16% | Saham |
| JONES FINANCIAL COMPANIES LLLP | $431.938.990 | 1.696.140 | 0,16% | Saham |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | $429.122.801 | 1.833.813 | 0,16% | Saham |
| PINNACLE ASSOCIATES LTD | $420.805.981 | 1.656.912 | 0,15% | Saham |
| WELLCOME TRUST LTD (THE) as trustee of the WELLCOME TRUST | $406.352.000 | 1.600.000 | 0,15% | Saham |
| Brandywine Global Investment Management, LLC | $403.777.662 | 1.951.088 | 0,15% | Saham |
| PFA Pension, Forsikringsaktieselskab | $403.665.514 | 1.589.422 | 0,15% | Saham |
| LONDON CO OF VIRGINIA | $393.611.148 | 1.549.812 | 0,14% | Saham |
| Focus Partners Wealth | $377.984.622 | 1.488.289 | 0,14% | Saham |
| CITADEL ADVISORS LLC | $374.150.636 | 1.473.208 | 0,14% | Saham |
| Baird Financial Group, Inc. | $370.780.061 | 1.459.936 | 0,13% | Saham |
| Zurcher Kantonalbank (Zurich Cantonalbank) | $359.417.836 | 1.415.198 | 0,13% | Saham |
| LAZARD ASSET MANAGEMENT LLC | $345.296.169 | 1.359.594 | 0,13% | Saham |
| KEYBANK NATIONAL ASSOCIATION/OH | $343.492.962 | 1.352.494 | 0,12% | Saham |
| BANK OF MONTREAL /CAN/ | $337.932.736 | 1.330.601 | 0,12% | Saham |
| Mitsubishi UFJ Trust & Banking Corp | $337.446.383 | 1.328.686 | 0,12% | Saham |
| SEB Asset Management AB | $331.038.376 | 1.303.456 | 0,12% | Saham |
| COMGEST GLOBAL INVESTORS S.A.S. | $327.501.426 | 1.289.528 | 0,12% | Saham |
| STATE OF WISCONSIN INVESTMENT BOARD | $326.163.258 | 1.284.259 | 0,12% | Saham |
| ROYAL BANK OF CANADA | $324.447.000 | 1.277.500 | 0,12% | Opsi beli |
| YACKTMAN ASSET MANAGEMENT LP | $319.996.359 | 1.259.977 | 0,12% | Saham |
Orang dalam perusahaan 75 orang dalam · 20 pejabat · 22 direktur
| Orang Dalam | Peran | Aktivitas terakhir | Saham dimiliki | Beli 12m | Jual 12m | Bersih 12m |
|---|---|---|---|---|---|---|
| Joseph J Wolk | Exec VP, CFO | 17 Feb. 2026 M | 14.000 | 0 | 4 | $-21.767.827 |
| Jennifer L Taubert | EVP, WWC. Innovative Medicine | 17 Agu 2026 M | 194.451 | 0 | 2 | $-13.991.509 |
| Vanessa Broadhurst | EVP, Global Corp Affairs | 20 Juli 2026 M | 23.003 | 0 | 2 | $-7.301.067 |
| Kathryn E Wengel | EVP, Chief TO and Risk Officer | 11 Juni 2026 M | 114.288 | 0 | 1 | $-2.411.500 |
| REED JOHN C | EVP, Innovative Medicine, R&D | 1 Mei 2026 M | 24.911 | 0 | 4 | $-17.291.087 |
| Robert J Decker | VP Corporate Controller | 27 Feb. 2026 M | 23.682 | 0 | 1 | $-1.010.070 |
| Timothy Schmid | EVP, WW Chair, MedTech | 20 Feb. 2026 S | 25.447 | 0 | 3 | $-5.852.269 |
| James D. Swanson | EVP, CIO | 17 Feb. 2026 M | 25.698 | 0 | 3 | $-15.109.760 |
| Kristen Mulholland | EVP, Chief HR Officer | 15 Feb. 2026 A | 19.830 | 0 | 0 | $0 |
| Stephen J Cosgrove | Corporate Controller | 9 Feb. 2015 A | 97.011 | 0 | 0 | $0 |
| Russell C Deyo | VP, General Counsel | 22 Feb. 2012 S | 2.478 | 0 | 0 | $0 |
| Sherilyn S Mccoy | Member, Executive Committee | 31 Jan. 2012 J | 6.455 | 0 | 0 | $0 |
| Colleen A Goggins | Member, Executive Committee | 10 Jan. 2011 A | 107.832 | 0 | 0 | $0 |
| Kaye I Foster-Cheek | VP, Human Resources | 31 Des. 2009 A | 1.181 | 0 | 0 | $0 |
| Christine A Poon | Vice Chairman | 13 Feb. 2009 M | 55.711 | 0 | 0 | $0 |
| Donald M Casey Jr. | Member, Executive Committee | 11 Feb. 2009 M | 26.095 | 0 | 0 | $0 |
| Robert J Darretta | Vice Chairman | 16 Feb. 2007 A | 1.938 | 0 | 0 | $0 |
| Per A Peterson | Executive Committee Member | 31 Jan. 2007 J | 790 | 0 | 0 | $0 |
| Michael J Dormer | Member, Executive Committee | 24 Okt. 2006 M | 878 | 0 | 0 | $0 |
| Joann Heffernan Heisen | VP, Chief Information Officer | 30 Des. 2005 J | 4.996 | 0 | 0 | $0 |
| Eugene A. Woods | Direktur | 9 Juni 2026 A | — | 0 | 0 | $0 |
| Daniel E Pinto | Direktur | 9 Juni 2026 A | — | 0 | 0 | $0 |
| Marillyn A Hewson | Direktur | 9 Juni 2026 A | 3.000 | 0 | 0 | $0 |
| Nadja West | Direktur | 23 April 2026 A | — | 0 | 0 | $0 |
| Mark A Weinberger | Direktur | 23 April 2026 A | 1.000 | 0 | 0 | $0 |
| Jennifer A Doudna | Direktur | 23 April 2026 A | — | 0 | 0 | $0 |
| Mark B. Mcclellan | Direktur | 23 April 2026 A | — | 0 | 0 | $0 |
| Mary C Beckerle | Direktur | 23 April 2026 A | — | 0 | 0 | $0 |
| Hubert Joly | Direktur | 23 April 2026 A | 5.000 | 0 | 0 | $0 |
| Paula A Johnson | Direktur | 23 April 2026 A | — | 0 | 0 | $0 |
| John G Morikis | Direktur | 23 April 2026 A | 1.849 | 1 | 0 | $257.688 |
| Susan L Lindquist | Direktur | 6 Sep. 2016 A | 14.605 | 0 | 0 | $0 |
| Mary Sue Coleman | Direktur | 8 Feb. 2016 A | 11.952 | 0 | 0 | $0 |
| Leo F Mullin | Direktur | 9 Feb. 2015 A | 26.195 | 0 | 0 | $0 |
| James Cullen | Direktur | 9 Feb. 2015 A | 1.489 | 0 | 0 | $0 |
| Michael M E Johns | Direktur | 10 Feb. 2014 A | 14.356 | 0 | 0 | $0 |
| David Satcher | Direktur | 11 Feb. 2013 A | 15.393 | 0 | 0 | $0 |
| Arnold G Langbo | Direktur | 9 Maret 2010 J | 424 | 0 | 0 | $0 |
| Steven Reinemund | Direktur | 11 Maret 2008 J | 7.567 | 0 | 0 | $0 |
| Ann Dibble Jordan | Direktur | 13 Maret 2007 J | 13.290 | 0 | 0 | $0 |
| JOHNSON & JOHNSON | Pemilik 10% | 28 April 2004 C | 4.448.076 | 0 | 0 | $0 |
| Joaquin Duato | — | 13 Agu 2026 M | 275.967 | 0 | 7 | $-89.386.933 |
| Elizabeth Forminard | — | 6 Agu 2026 M | 16.994 | 0 | 2 | $-4.090.993 |
| Darius Adamczyk | — | 25 April 2024 A | — | 0 | 0 | $0 |
| Scott D Davis | — | 25 April 2024 A | — | 0 | 0 | $0 |
| Anne M Mulcahy | — | 25 April 2024 A | 6.537 | 0 | 0 | $0 |
| William Hait | — | 15 Feb. 2024 A | 38.647 | 0 | 0 | $0 |
| Peter Fasolo | — | 15 Feb. 2024 A | 112.076 | 0 | 0 | $0 |
| Ashley Mcevoy | — | 23 Agu 2023 D | 52.038 | 0 | 0 | $0 |
| Eugene A. Washington | — | 7 Maret 2023 A | — | 0 | 0 | $0 |
Orang dalam dari pengajuan SEC Form 3/4/5; bersih = hanya P/S pasar terbuka
Aktivis & pemilik 5%+ 4 saham
Investor yang mengajukan Jadwal 13D SEC — kepemilikan manfaat di atas 5% dengan niat untuk memengaruhi penerbit (kepemilikan aktivis, kampanye dewan, M&A). Setiap baris menunjukkan status terbaru yang diketahui dari posisi pengaju tersebut.
| Pengaju | Diajukan | Kepemilikan | Status | Tujuan | Pengajuan |
|---|---|---|---|---|---|
| Johnson & Johnson ×7 pengajuan | 6 Des. 2010 | — | Pengajuan awal | — | SEC |
| Orang pelapor yang tidak diungkapkan | 27 Jan. 2003 | — | Pengajuan awal | — | SEC |
| Orang pelapor yang tidak diungkapkan | 21 Nov. 2002 | — | Pengajuan awal | — | SEC |
| Orang pelapor yang tidak diungkapkan | 5 Feb. 2001 | — | Pengajuan awal | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Kepemilikan ETF Dimiliki oleh 318 ETF
Bobot mencerminkan kepemilikan ekuitas langsung (N-PORT) saja; dana berbasis leverage atau derivatif mungkin memiliki eksposur swap tambahan yang tidak ditampilkan.
| Dana | Bobot | Unit | Per tanggal | Sumber |
|---|---|---|---|---|
| IHE · iShares Trust | 22,16% | 1.426.758 SH | 21 Agu 2026 | Harian |
| IYH · iShares Trust | 9,95% | 1.437.371 SH | 21 Agu 2026 | Harian |
| FHLC · FIDELITY COVINGTON TRUST | 8,94% | 1.110.650 NS | 30 April 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 8,89% | 7.140.555 SH | 19 Agu 2026 | Harian |
| GDOC · Goldman Sachs ETF Trust | 8,07% | 7.204 NS | 31 Mei 2026 | N-PORT |
| CURE · Direxion Shares ETF Trust | 7,99% | 48.053 NS | 30 April 2026 | N-PORT |
| RXL · ProShares Trust | 7,86% | 25.129 NS | 31 Mei 2026 | N-PORT |
| FTXH · First Trust Exchange-Traded Fund VI | 6,96% | 9.939 NS | 30 Juni 2026 | N-PORT |
| IXJ · iShares Trust | 6,91% | 1.124.264 SH | 21 Agu 2026 | Harian |
| JDOC · J.P. Morgan Exchange-Traded Fund Tr… | 6,20% | 3.001 NS | 30 April 2026 | N-PORT |
| DIVL · Madison ETFs Trust | 5,49% | 12.987 NS | 30 Juni 2026 | N-PORT |
| PJP · Invesco Exchange-Traded Fund Trust | 5,09% | 100.619 SH | 21 Agu 2026 | Harian |
| OUSA · ALPS ETF Trust | 5,06% | 166.868 NS | 31 Mei 2026 | N-PORT |
| SPMO · Invesco Exchange-Traded Fund Trust … | 4,64% | 3.827.496 SH | 21 Agu 2026 | Harian |
| SPVU · Invesco Exchange-Traded Fund Trust … | 4,44% | 26.614 NS | 31 Mei 2026 | N-PORT |
| DJD · Invesco Exchange-Traded Fund Trust | 4,38% | 82.468 SH | 21 Agu 2026 | Harian |
| QLTY · GMO ETF Trust | 4,22% | 844.279 NS | 31 Mei 2026 | N-PORT |
| CCOR · Listed Funds Trust | 4,12% | 4.942 NS | 30 April 2026 | N-PORT |
| QLV · FlexShares Trust | 4,11% | 30.303 NS | 30 April 2026 | N-PORT |
| MTUM · iShares Trust | 3,63% | 3.366.987 SH | 21 Agu 2026 | Harian |
| PSIL · AdvisorShares Trust | 3,61% | 6.308 NS | 30 Juni 2026 | N-PORT |
| HRTS · Tema ETF Trust | 3,59% | 8.274 NS | 31 Mei 2026 | N-PORT |
| PWV · Invesco Exchange-Traded Fund Trust | 3,52% | 244.422 SH | 21 Agu 2026 | Harian |
| EDOW · First Trust Exchange-Traded Fund | 3,46% | 41.790 NS | 30 Juni 2026 | N-PORT |
| XT · iShares Trust | 3,43% | 504.767 SH | 21 Agu 2026 | Harian |
| RFFC · ALPS ETF Trust | 3,42% | 4.511 NS | 31 Mei 2026 | N-PORT |
| LCOW · Pacer Funds Trust | 3,27% | 3.266 NS | 30 April 2026 | N-PORT |
| AGQI · First Trust Exchange-Traded Fund VI… | 3,26% | 8.108 NS | 31 Mei 2026 | N-PORT |
| USMC · Principal Exchange-Traded Funds | 3,20% | 439.492 NS | 30 Juni 2026 | N-PORT |
| ESGG · FlexShares Trust | 3,19% | 15.060 NS | 30 April 2026 | N-PORT |
| DGRO · iShares Trust | 3,15% | 5.134.101 SH | 21 Agu 2026 | Harian |
| GEND · Spinnaker ETF Series | 3,10% | 599 | 30 April 2026 | N-PORT |
| FLV · AMERICAN CENTURY ETF TRUST | 3,08% | 48.203 NS | 31 Mei 2026 | N-PORT |
| TBG · EA Series Trust | 3,03% | 30.300 NS | 30 April 2026 | N-PORT |
| BDIV · ETF Series Solutions | 2,97% | 812 NS | 30 April 2026 | N-PORT |
| MGV · VANGUARD WORLD FUND | 2,88% | 1.513.022 SH | 19 Agu 2026 | Harian |
| AGNG · Global X Funds | 2,88% | 10.447 NS | 31 Mei 2026 | N-PORT |
| DJIA · Global X Funds | 2,87% | 21.113 NS | 30 April 2026 | N-PORT |
| YOKE · EA Series Trust | 2,87% | 28.113 NS | 30 April 2026 | N-PORT |
| DYLG · Global X Funds | 2,86% | 732 NS | 30 April 2026 | N-PORT |
| RFDA · ALPS ETF Trust | 2,82% | 10.938 NS | 31 Mei 2026 | N-PORT |
| CAPE · DoubleLine ETF Trust | 2,81% | 26.392 NS | 30 Juni 2026 | N-PORT |
| GDIV · Harbor ETF Trust | 2,76% | 27.085 NS | 30 April 2026 | N-PORT |
| ASLV · ALLSPRING EXCHANGE-TRADED FUNDS TRU… | 2,69% | 26.096 NS | 30 April 2026 | N-PORT |
| QDF · FlexShares Trust | 2,68% | 247.500 NS | 30 April 2026 | N-PORT |
| VIG · VANGUARD SPECIALIZED FUNDS | 2,66% | 13.599.531 SH | 19 Agu 2026 | Harian |
| BKDV · BNY Mellon ETF Trust II | 2,63% | 158.124 NS | 30 April 2026 | N-PORT |
| VLLU · Harbor ETF Trust | 2,62% | 496 NS | 30 April 2026 | N-PORT |
| TOPT · iShares Trust | 2,62% | 65.064 SH | 21 Agu 2026 | Harian |
| QDEF · FlexShares Trust | 2,58% | 59.511 NS | 30 April 2026 | N-PORT |